GENEMEDICS APP
GENEMEDICS NUTRITION
AOD 9604 offers primary benefits such as promoting weight loss and treating osteoarthritis, contributing to an overall enhancement in health.
Anti-Obesity Drug-9604 (AOD 9604 or AOD-9604) is a synthetic analog of the human growth hormone. Its main purpose is to fight obesity and help people trying to lose weight. This anti-obesity drug works by stimulating the pituitary gland and other hormones to speed up the body’s metabolism, resulting in faster weight loss.
AOD 9604 works by stimulating the body’s natural fat-burning process known as lipolysis. Lipolysis is the biological process of breaking down triglycerides (fats) stored in adipose tissue (fat cells) into their constituent components, namely glycerol and fatty acids. This process provides energy for the body when needed.
Here’s a step-by-step explanation of the lipolysis process:
AOD 9604, a synthetic peptide derived from the C-terminus of human growth hormone, is believed to promote weight loss by enhancing fat metabolism. Through a medical weight loss program, individuals seeking greater weight loss might be introduced to solutions like AOD 9604. Unlike the full-length growth hormone, AOD 9604 specifically targets fat cells, stimulating the breakdown of fat (lipolysis) and inhibiting the formation of new fat (lipogenesis). This makes it a promising candidate for those enrolled in a medical weight loss program aiming for a healthy weight.
Additionally, it doesn’t have adverse effects on blood sugar or tissue growth commonly associated with growth hormones. By integrating AOD 9604 peptide into a medical weight loss strategy, there’s potential for more significant weight loss, offering a focused approach to reducing body fat more effectively.
A number of high-quality studies suggest that AOD 9604 peptide has potent fat-burning properties necessary for medical weight loss:
AOD 9604 peptide has been studied not only for its potential weight loss benefits but also for its potential therapeutic effects on osteoarthritis and other bone disorders. The peptide is believed to promote cartilage regeneration and enhance collagen production, both vital for joint health, bone strength, and cartilage and bone repair. In the context of osteoarthritis, where cartilage degeneration occurs, AOD 9604 might help slow down this degeneration and possibly reverse some of the damage by promoting cartilage repair and aiding in cartilage and bone repair processes.
The potential of AOD 9604 in bone repair makes it a promising candidate for broader therapeutic applications. While promising, it’s essential to note that more comprehensive clinical trials and research are required to fully ascertain its efficacy and safety in promoting bone repair and treating osteoarthritis and other bone-related conditions.
AOD 9604 peptide has also been found to have regenerative properties that are essential for optimum bone health:
AOD 9604 side effects are very uncommon. There have been some side effects associated with the use of this drug wherein the patient had one of the issues listed below at some point while being on AOD 9604. However, these side effects weren’t confirmed to be associated with the treatment and could have been a coincidence and not related to the use of AOD 9604. Despite this, it was listed as a side effect associated with AOD 9604 even though these associated side effects are very uncommon.
Side effects associated with AOD 9604 may include the following:
Here’s a general breakdown of its dosage:
It’s important to stress that before starting AOD 9604 or any other peptide therapy, individuals should consult with a healthcare provider. This is essential to ensure that the peptide is appropriate for their specific circumstances, to confirm dosing guidelines, and to receive proper dosage instructions, which might include storing the peptide at a cool temperature or guidance on how it interacts with other injections. Adhering to these instructions can prevent potential adverse reactions. Furthermore, storing peptides like AOD 9604 at the recommended cool temperature can ensure its efficacy and longevity. Regular consultation allows for monitoring any side effects and adjusting treatment as necessary, especially when combined with other injections or medications.
AOD 9604, a synthetic peptide derived from human growth hormone, has garnered attention for its potential role in promoting fat metabolism and weight loss. Before starting the treatment, many individuals seeking weight management solutions often find themselves struggling with persistent fat pockets despite adhering to a regular exercise routine and a healthy diet such as a lower-calorie diet. They might experience slow metabolism and find it challenging to shed those extra pounds.
After several weeks to months of AOD 9604 administration, some users report noticeable changes. There’s often a reduction in stubborn fat areas, an uptick in metabolic rates, and, in some instances, overall weight loss. Enhanced energy levels and an improved sense of well-being are also anecdotal outcomes associated with the peptide. However, it’s essential to note that individual results can vary greatly. While some might observe significant changes, others might experience subtler shifts.
Additionally, the effectiveness of AOD 9604 can be influenced by factors like diet, exercise routines, and individual physiological responses such as the body’s metabolism. To see results, it’s crucial to maintain a balanced approach and make necessary adjustments based on how one’s body reacts. Some users might experience side effects, highlighting the importance of monitoring and consultation with healthcare professionals. This ensures safety and efficacy in one’s journey with AOD 9604.
AOD 9604 and semaglutide are both substances that have been researched for their potential effects on weight management, but they function through different mechanisms and have different primary purposes. Here’s a comparison:
AOD 9604
Semaglutide
While both AOD 9604 and semaglutide have implications in weight management, they are distinct in their modes of action and approval status. Semaglutide has robust clinical data supporting its efficacy and safety in weight management, and it’s approved for such use. In contrast, AOD 9604 is still in the realm of research and anecdotal evidence, with its safety and efficacy yet to be conclusively determined.
Before considering either for weight management, it’s crucial to consult with a healthcare professional to understand potential risks, benefits, and to determine which, if any, is suitable for individual circumstances.
AOD 9604 and ipamorelin are both peptides that have been studied for their potential benefits in the realm of health and wellness, particularly around weight management and anti-aging. However, their mechanisms of action, primary uses, and effects can differ significantly. Let’s explore their distinctions:
AOD 9604
Ipamorelin
While both AOD 9604 and ipamorelin might play roles in fat metabolism, they operate primarily via different pathways. AOD 9604 directly targets fat metabolism, whereas ipamorelin’s potential fat-reducing properties are more indirect, resulting from the increased growth hormone levels it induces. Furthermore, ipamorelin’s benefits extend beyond fat metabolism to include muscle growth and recovery due to its influence on GH.
For individuals interested in muscle growth, recovery, and potentially some fat metabolism, ipamorelin might be a consideration. However, it’s important to be aware of any negative effects, especially if there’s a family history of related health concerns. On the other hand, those strictly looking for weight loss and fat reduction might lean more toward AOD 9604. Before making any decision, it’s crucial to consider one’s family history and any predispositions to health issues to ensure a safe and effective approach.
AOD 9604, a synthetic peptide associated with fat metabolism and weight loss, has seen fluctuating prices influenced by various determinants. Primarily, the supplier’s reputation and product purity can significantly affect costs, with higher purity and established brands often commanding steeper prices. Geographical factors, such as regional demand, regulations, and shipping considerations, can also result in price discrepancies. The form of the peptide, whether it’s a lyophilized powder, liquid solution, or another form, can introduce additional price variations. Bulk purchasing may offer savings, though it’s essential to consider the product’s shelf life.
Dr. George Shanlikian, renowned as the world’s best hormone therapy doctor, possesses expertise in various medical domains. These include Bio-Identical Hormone Replacement Therapy, Peptide Replacement Therapy, Anti-Aging Medicine, Regenerative Medicine, Stress Management, Nutrition Consulting, Nutritional Supplement Consulting, and Exercise Consulting.
Read more about him here: https://www.genemedics.com/dr-george-shanlikian-md-best-hormone-therapy-doctor
Read more success stories here:
Men’s Success Stories: https://www.genemedics.com/about-ghi/ghi-success-stories/mens-success-stories/
Women’s Success Stories: https://www.genemedics.com/about-ghi/ghi-success-stories/womens-success-stories/
AOD 9604 has been formulated in various forms, including nasal sprays and reconstituted peptides for subcutaneous injection. However, the efficacy of the nasal spray form compared to other delivery methods, like subcutaneous injection of reconstituted peptides, requires further research. Anecdotal reports vary, and it’s essential to consult with a healthcare professional about its effectiveness for individual circumstances.
AOD 9604 is often referred to as “Anti-Obesity Drug-9604.”
The efficacy of topical AOD 9604 formulations is still a subject of research and debate. Personal attributes, such as skin type and metabolic rate, along with the use of other medications, can influence individual reactions to the product. Some anecdotal reports suggest benefits, but comprehensive scientific evidence is limited compared to other delivery methods. It’s essential to consider these personal attributes and interactions with other medications when evaluating the potential effects of AOD 9604.
No. While both are derived from the C-terminus of the human growth hormone molecule, they represent different fragments. AOD 9604 covers the sequence 177-191, while frag 176-191 is slightly different. Both are studied for fat loss, but they are distinct peptides.
AOD9604 is a synthetic peptide derived from the C-terminus, a fragment of human growth hormone. This particular segment has shown promising characteristics distinct from the entire hormone. It has been researched for its potential to promote fat metabolism and weight loss without the side effects typically associated with full-length growth hormone.
Frag 176 refers to a portion of the human growth hormone molecule, specifically the fragment 176-191. AOD 9604 is a slightly different fragment, representing the sequence 177-191 of the growth hormone. Both peptides have been studied for weight loss and fat metabolism.
AOD 9604 is a synthetic peptide. While often referred to in some contexts as a drug, it’s crucial to understand its properties and potential effects. Some substances can interact adversely with AOD 9604, so it’s always recommended to seek a free consultation with a healthcare professional before starting any regimen with this peptide.
AOD-9604 is primarily researched for its potential fat metabolism properties, distinguishing it from other growth hormones. CJC 1295, on the other hand, is a growth hormone-releasing hormone (GHRH) analog studied for its potential to boost growth hormone production. While both are peptides and have their roots in growth hormone research, they serve different primary purposes and mechanisms, with AOD-9604 focusing on fat metabolism and CJC 1295 enhancing overall growth hormone levels.
Results may vary based on dosage levels and individual responses. However, some users report a plateau in weight loss or a return to previous weight levels if they cease taking peptides for weight loss without maintaining a healthy diet and exercise regime. It’s worth noting that while on peptides, the right dosage levels can yield significant results, but discontinuation can potentially reverse some of these gains unless complemented by consistent lifestyle choices.
Dosage and frequency depend on the specific peptide and individual goals. While some might seek immediate results, it’s crucial to understand that the efficacy of peptides can vary, especially when compared to other supplements. Given the known health risks associated with incorrect dosages, misuse, or interactions with other supplements, consulting with a healthcare professional is essential for personalized advice and safe usage.
Some peptides, especially those influencing growth hormone release, are often taken at night to align with the body’s natural circadian rhythm of growth hormone production. It’s recommended that these peptides be taken on an empty stomach to maximize their effectiveness and reduce the potential for an upset stomach. Consuming them without food can help prevent any digestive disturbances or reduced absorption.
The half-life and duration of peptides in the bloodstream vary based on the specific peptide. Many have short half-lives of minutes to hours, but this can differ.
Weight loss results can vary based on the peptide, individual physiology, diet, exercise, dosage cycle, and other factors. Some users report significant weight loss, while others experience more modest results. For those considering using peptides for weight management, looking into AOD 9604 weight loss reviews might offer valuable insights from individuals who have tried the treatment and can shed light on its potential benefits and limitations. Additionally, if someone decides that this is the right choice for them, they might explore where to buy AOD 9604 from reputable sources to ensure product authenticity and quality.
Side effects depend on the specific peptide. Common side effects might include irritation at the injection site, fatigue, water retention, or increased hunger. It’s crucial to monitor responses and consult with a healthcare professional. There are risks associated with any medication or supplement, so understanding and being vigilant about potential side effects is essential for safety and overall health.
The method depends on the peptide. Many are taken via subcutaneous injection, including AOD 9604 injections, which are popular among those seeking its benefits. For optimal results with AOD 9604, it’s recommended to inject the peptide about 30 minutes before eating. This can help maximize the peptide’s effects in conjunction with food intake. However, there are also oral, topical, and nasal formulations for specific peptides. It’s worth noting that, while injections might offer more direct delivery, some individuals might experience side effects from oral formulations.
A troche is a small lozenge designed to dissolve slowly in the mouth, allowing for the gradual absorption of its active ingredients. An AOD 9604 troche is, therefore, a lozenge form of the AOD 9604 peptide. This delivery method provides an alternative to injections, aiming to deliver the peptide into the bloodstream through the mucous membranes of the mouth. Additionally, there are AOD 9604 tablets available that offer another potential method of administration. The efficacy, absorption rate, and bioavailability of AOD 9604 when taken as a troche or in tablet form, compared to other delivery methods, such as subcutaneous injection, might vary. It’s essential to consult with a healthcare professional before starting any form of peptide therapy.
Ng FM, Sun J, Sharma L, Libinaka R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-8. doi: 10.1159/000053183. PMID: 11146367.
Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone
An investigation into the metabolic effects of AOD9604, a synthetic analogue mimicking the lipolytic segment of human growth hormone (hGH), was conducted on obese Zucker rats. Over a 19-day period, daily oral administration of AOD9604 at a dose of 500 microg/kg significantly reduced body weight gain by more than 50% compared to the control group (15.8 +/- 0.6 g vs. 35.6 +/- 0.8 g). AOD9604-treated rats exhibited increased lipolytic activity in their adipose tissues. Importantly, unlike chronic treatment with intact hGH, chronic AOD9604 treatment had no adverse impact on insulin sensitivity, as confirmed through euglycemic clamp techniques. These findings suggest that the hGH lipolytic domain analogue may have potential as a safe and orally administered therapeutic agent for obesity.
You can read the abstract of the article at https://karger.com/hrp/article-abstract/53/6/274/371690/Metabolic-Studies-of-a-Synthetic-Lipolytic-Domain?redirectedFrom=fulltext.
Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001 Oct;25(10):1442-9. doi: 10.1038/sj.ijo.0801740. PMID: 11673763.
Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment
The study aimed to investigate the chronic effects of human growth hormone (hGH) and AOD9604 (a C-terminal fragment of hGH) on body weight, energy balance, and substrate oxidation rates in obese (ob/ob) and lean C57BL/6J mice. Both hGH and AOD significantly reduced body weight gain in obese mice, accompanied by increased in vivo fat oxidation and higher plasma glycerol levels, indicating enhanced lipolysis. Unlike hGH, AOD9604 did not lead to hyperglycemia or decreased insulin secretion. Importantly, AOD9604 did not compete for the hGH receptor and did not induce cell proliferation, distinguishing it from hGH. This study further supports the idea that hGH acts as a pro-hormone, and fragments of hGH can exert unique effects distinct from traditional hGH-stimulated pathways.
You can read the abstract of the article at https://pubmed.ncbi.nlm.nih.gov/11673763/.
Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001 Dec;142(12):5182-9. doi: 10.1210/endo.142.12.8522. PMID: 11713213.
The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice
Both human GH (hGH) and a lipolytic fragment called AOD9604, derived from its C-terminus, have the ability to induce weight loss and increase sensitivity to fat breakdown in mice following long-term treatment. One possible mechanism involves their interaction with the beta-adrenergic pathway, particularly the beta(3)-adrenergic receptors (beta(3)-AR). This study reveals that hGH and AOD9604 can reduce body weight and fat content in obese mice by increasing the expression of beta(3)-AR RNA, the primary receptor involved in fat cell breakdown. Notably, both hGH and AOD9604 can elevate beta(3)-AR RNA levels in obese mice to levels similar to those in lean mice. Confirming the role of beta(3)-AR, long-term treatment with hGH and AOD9604 did not produce the same weight loss and lipolysis increase in beta(3)-AR knock-out mice. However, in a short-term experiment, AOD9604 increased energy expenditure and fat oxidation in these mice. In summary, while the lipolytic actions of hGH and AOD9604 are not directly mediated by beta(3)-AR, both compounds enhance beta(3)-AR expression, which may contribute to improved sensitivity to fat breakdown.
You can read the full article at https://academic.oup.com/endo/article/142/12/5182/2988749?login=false.
Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment
The chronic effects of human growth hormone (hGH) and AOD9604, a C-terminal fragment of hGH, were examined in obese and lean mice. They were administered hGH, AOD9604, or saline for 14 days. Both hGH and AOD9604 significantly reduced body weight gain in obese mice and increased fat oxidation and plasma glycerol levels. Notably, AOD9604 didn’t induce hyperglycemia or reduce insulin secretion as hGH did. In vitro studies confirmed that AOD9604 doesn’t interact with the hGH receptor or induce cell proliferation, in contrast to hGH. This research suggests that both hGH and its C-terminal fragment can reduce body weight gain and promote fat oxidation and lipolysis in obese mice, with AOD9604 acting through novel pathways distinct from hGH.
You can read the abstract of the article at https://www.researchgate.net/publication/11678445_Increase_of_fat_oxidation_and_weight_loss_in_obese_mice_caused_by_chronic_treatment_with_human_growth_hormone_or_a_modified_C-terminal_fragment.
Available at https://journals.physiology.org/doi/full/10.1152/ajpendo.2000.279.3.E501.
Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism
AOD-9401, a synthetic peptide sequence of human growth hormone (hGH), demonstrates lipolytic and antilipogenic activities akin to the complete hormone. In studies with obese rodent models and human adipose tissue, it was found that oral AOD-9401 treatment reduced weight gain in rodents without altering food consumption. This effect is attributed to modifications in lipid metabolism, increasing energy expenditure, glucose and fat oxidation, and adjustments in lipogenic and lipolytic activities in both rodent and human adipose tissues. These results suggest AOD-9401’s potential as a treatment for human obesity.
You can read the full article at https://journals.physiology.org/doi/full/10.1152/ajpendo.2000.279.3.E501.
Judith Korner, Louis J. Aronne, Pharmacological Approaches to Weight Reduction: Therapeutic Targets, The Journal of Clinical Endocrinology & Metabolism, Volume 89, Issue 6, 1 June 2004, Pages 2616–2621, https://doi.org/10.1210/jc.2004-0341.
Pharmacological Approaches to Weight Reduction: Therapeutic Targets
Obesity is a chronic condition marked by the excessive accumulation of fat tissue, linked to various health risks and increased mortality. Weight loss can mitigate many obesity-related health issues, but the body’s neuroendocrine responses often counteract attempts to shed excess weight by increasing appetite and reducing energy expenditure as protective mechanisms. This makes voluntary weight loss through caloric restriction challenging. Hence, pharmacological interventions are frequently required to facilitate weight loss and its maintenance. This review provides an overview of current obesity pharmacotherapy and explores how advancements in understanding the intricate energy regulation network may lead to more precise and efficient treatments.
You can read the full article at https://academic.oup.com/jcem/article/89/6/2616/2870295?login=false.
Misra M. Obesity pharmacotherapy: current perspectives and future directions. Curr Cardiol Rev. 2013;9(1):33-54. doi:10.2174/157340313805076322.
Obesity pharmacotherapy: current perspectives and future directions
Obesity is a global health crisis, demanding effective solutions beyond the limited medications currently available. Recent insights into the neuroendocrine mechanisms governing body weight regulation have unveiled a growing array of molecular targets for innovative anti-obesity drugs. These medications act through four primary mechanisms: reducing energy intake, enhancing energy expenditure or influencing lipid metabolism, regulating fat stores or adipocyte development, and simulating caloric restriction. Multiple novel drug candidates and targets are under investigation, with some advancing to advanced clinical trial stages. This review delves into the development of new anti-obesity drugs, rooted in our contemporary comprehension of energy balance.
You can read the full article at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3584306/.
Available from https://www.news-medical.net/news/2004/12/16/6878.aspx.
Obesity drug codenamed AOD9604 highly successful in trials
An Australian biotechnology company, Metabolic Pharmaceuticals Limited, developed an obesity drug, codenamed AOD9604, that’s advancing to final human trials following successful Phase 2b results. This drug, unique in its approach, stimulates the metabolism of body fat, unlike other obesity drugs which reduce appetite or food absorption. In a 12-week trial involving 300 obese patients, the 1mg dose proved most effective, resulting in an average weight loss of 2.8 kilograms—surpassing results from other leading prescription obesity medications without their side effects. Moreover, there was an improvement in cholesterol profiles and a decrease in patients with impaired glucose tolerance after 12 weeks.
You can read the full article at https://www.news-medical.net/news/2004/12/16/6878.aspx.
Available from https://onlinelibrary.wiley.com/doi/full/10.1038/oby.2006.294.
Herd, C., Wittert, G., Caterson, I., et al. The effect of AOD9604 on weight loss in obese adults: results of a randomized, double-blind, placebo-controlled, multicenter study 2005 Annual Scientific Meeting of the North American Association for the Study of Obesity, October 18, 2005, Vancouver, British Columbia, Canada.
Kwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. 2015 Summer;45(4):426-32. PMID: 26275694.
Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model
This study aimed to explore the effects of AOD9604 administered intra-articularly, both independently and in conjunction with hyaluronic acid (HA), in a rabbit model of collagenase-induced knee osteoarthritis (OA). Rabbits received various treatments for 4-7 weeks following collagenase injections into their knee joints. Results indicated that the combination of AOD9604 and HA (Group 4) was the most effective in reducing cartilage degeneration compared to other groups, including saline, HA alone, and AOD9604 alone. Furthermore, Group 4 also exhibited a shorter period of lameness, highlighting the potential benefits of this combination therapy in the treatment of collagenase-induced knee OA in rabbits.
You can read the full article at http://www.annclinlabsci.org/content/45/4/426.long.
Gu F, Jiang J, Wang S, et al. An experimental research into the potential therapeutic effects of Anti-Osteoporosis Decoction and Yougui Pill on ovariectomy-induced osteoporosis. Am J Transl Res. 2019;11(9):6032-6039. Published 2019 Sep 15.
An experimental research into the potential therapeutic effects of Anti-Osteoporosis Decoction and Yougui Pill on ovariectomy-induced osteoporosis
This study aimed to investigate the potential therapeutic effects of the Anti-Osteoporosis Decoction (AOD) and Yougui Pill (YGP) in an ovariectomy-induced rat model of osteoporosis. The study successfully established the osteoporosis model and found that treatment with AOD and YGP effectively inhibited osteoporosis, improved bone density, and reduced trabecular bone damage. These treatments also increased levels of bone-related proteins, such as BMP2, Runx2, Collagen I, and On, while decreasing levels of PINP and β-CTX in serum compared to the osteoporosis model group. These findings suggest that AOD and YGP have potential therapeutic benefits for osteoporosis in ovariectomized rats and may hold promise for human osteoporosis treatment.
You can read the full article at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789260/.
At the age of 60, I look and feel better than I ever have in my entire life! Switching my health program and hormone replacement therapy regimen over to Genemedics was one of the best decisions I’ve ever made in my life! Genemedics and Dr George have significantly improved my quality of life and also dramatically improved my overall health. I hav...
Nick Cassavetes ,60 yrs old
Movie Director (“The Notebook”, “John Q”, “Alpha Dog”), Actor and Writer
I am now in my mid-sixties and feel better than I did in my 20’s. Many people have commented that I actually look 20 years younger since I started the program at Genemedics.
Calling Dr. George has proven to be one of the best decisions I have made in my life. Doctors and society convince us that developing various health issues and negative sy...
Pamela Hill ,66 yrs old
Call 800-277-4041 for a Free Consultation
Genemedics® Health Institute is a global premier institute dedicated to revolutionizing health and medicine through healthy lifestyle education, guidance and accountability in harmony with functional medicine. Our physician-supervised health programs are personally customized to help you reach your health and fitness goals while looking and feeling better than ever.
© Copyright Genemedics Health Institute. All Rights Reserved. Privacy Policy.
STEPS AWAY FROM A YOUNGER. HEALTHIER YOU!
Call 800-277-4041 for a Free Consultation
What to expect during your consultation: